Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -1.01x is 76% above its 4-year average of -4.14x, near the high end of its 4-year range (-34.07x–6.13x).
174.02% below its 12-month average of 1.36x.
Reported quarterly interest coverage; no daily interpolation. Q2 FY2026 (2026-06-30): 4.82x.
INTEREST COVERAGE RATIO
-1.01x
INTEREST COVERAGE RATIO AVG TTM
1.36x
INTEREST COVERAGE RATIO AVG 3Y
-3.19x
INTEREST COVERAGE RATIO AVG 5Y
N/A
INTEREST COVERAGE RATIO AVG 10Y
N/A
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-174.02%
CURRENT VS 3Y AVG
+68.30%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-4.24x
median of 361 covered companies
CURRENT VS SECTOR MEDIAN
+76.18%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$3.04B
Interest Coverage Ratio
-1.01x
TTM Avg
1.36x
3Y Avg
-3.19x
5Y Avg
N/A
Market Cap
$3.05B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.01B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.09B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.83B
Interest Coverage Ratio
7.88x
TTM Avg
5.24x
3Y Avg
5.24x
5Y Avg
5.24x
Market Cap
$2.81B
Interest Coverage Ratio
-0.59x
TTM Avg
11.23x
3Y Avg
11.23x
5Y Avg
11.23x
Market Cap
$2.80B
Interest Coverage Ratio
-75.61x
TTM Avg
0.12x
3Y Avg
0.12x
5Y Avg
0.12x
Market Cap
$2.71B
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.71B
Interest Coverage Ratio
1.89x
TTM Avg
1.89x
3Y Avg
0.94x
5Y Avg
0.94x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.04B | -1.01x | 1.36x | -3.19x | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.05B | N/A | N/A | N/A | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.01B | N/A | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.09B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.83B | 7.88x | 5.24x | 5.24x | 5.24x |
| AtriCure, Inc. (ATRC)vs › | $2.81B | -0.59x | 11.23x | 11.23x | 11.23x |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.80B | -75.61x | 0.12x | 0.12x | 0.12x |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | N/A | N/A | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.71B | 1.89x | 1.89x | 0.94x | 0.94x |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.40B | N/A | 407.95x | 407.95x | 407.95x |
Interest Coverage
-1.0x
Debt/Equity
0.52
Current Ratio
2.92
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2026-06-30 | 4.82x |
| 2026-03-31 | -2.08x |
| 2025-12-31 | 6.13x |
| 2025-09-30 | 2.78x |
| 2025-06-30 | -4.82x |
| 2025-03-31 | -8.23x |
| 2024-12-31 | -1.37x |
| 2024-09-30 | -5.87x |
| 2024-06-30 | -6.69x |
| 2024-03-31 | -4.23x |
| 2023-12-31 | -7.88x |
| 2023-09-30 | -4.88x |
| 2023-06-30 | -9.08x |
| 2023-03-31 | -10.83x |
| 2022-12-31 | -9.90x |
| 2022-09-30 | -21.38x |
| 2022-06-30 | -32.91x |
| 2022-03-31 | -34.07x |
